Document:

Exhibit 10.15

 

ESCROW AGREEMENT

 

This ESCROW AGREEMENT
(this “Agreement”) made as of the 24th day of December, 2014 (the “Effective Date”), by and
between Axxess Pharma, Inc. (the “Company”), Beaufort Capital Partners LLC (the “Investor”),
and Matthew McMurdo, Esq. (the “Escrow Agent”).

 

WITNESSETH:

 

WHEREAS, the Investor
proposes to provide the legal expenses related to the definitive documents required for an equity line financing (the “Expenses”),
on behalf of the Company, necessary to file a registration statement on Form S-1 (the “S-1”), pursuant to a
registration rights agreement, by and between the Investor and the Company, dated December 23, 2014 (the “Registration
Rights Agreement”);

 

WHEREAS, in return
for payment of the Expenses, the Company has agreed to deposit 1,000,000 shares of its common stock (the “Shares”)
into an escrow account (the “Escrow Account”); and

 

WHEREAS, the Escrow
Agent has agreed to hold the Shares as Escrow Agent pursuant to the terms of this agreement.

 

NOW, THEREFORE, in
consideration of the premises and mutual covenants herein contained, the parties hereto hereby agree as follows:

 

1.          Deposit.
The Company shall promptly deliver a certificate covering the Shares, along with an executed stock power, to the Escrow Agent at
the following address:

 

Matthew McMurdo, Esq.

28 West 44th
Street

16th Floor

New York, NY 10036

 

2.          Disbursement
of the Shares.

 

2.1           The
Escrow Agent shall deliver the Shares to the Company upon the Securities and Exchange Commission (the “SEC”)
declaring the S-1 effective.

 

2.2           If
(i) the Registration Statement does not become effective within 12 months following the date of the Investment Agreement, or (ii)
there is a breach of any material term of the Registration Rights Agreement, the Escrow Agent shall deliver the Shares to the Investor.

 

    	 

    	 

    

 

2.3           Upon
disbursement of the Shares, letter(s) of instruction and related documents, pursuant to the terms of Section 2.1 or 2.2, the Escrow
Agent shall be relieved of further obligations and released from all liability under this Agreement.

 

3.          Rights,
Duties and Responsibilities of Escrow Agent. It is understood and agreed that the duties of the Escrow Agent are purely ministerial
in nature, and that:

 

3.1           The
Escrow Agent shall notify the parties hereto of his receipt of the Shares.

 

3.2           The
Escrow Agent shall not be responsible for the performance by the Company or the Investor of their respective obligations under
this Agreement or the Registration Rights Agreement.

 

3.3           If
the Escrow Agent is uncertain as to its duties or rights hereunder or shall receive instructions with respect to the Escrow Account
which, in his sole determination, are in conflict either with any provision of this Agreement, he shall deposit the Shares with
the court for the resolution of such dispute by final judgment of a court of competent jurisdiction or otherwise.

 

3.4           The
Escrow Agent shall not be liable for any action taken or omitted hereunder, or for the misconduct of any employee, agent or attorney
appointed by it, except in the case of willful misconduct or gross negligence. The Escrow Agent shall be entitled to consult with
counsel of its own choosing and shall not be liable for any action taken, suffered or omitted by it in accordance with the advice
of such counsel.

 

3.5           The
Escrow Agent shall have no responsibility at any time to ascertain whether or not any security interest exists in the Escrow Amount
or any part thereof or to file any financing statement under the Uniform Commercial Code with respect to the Escrow Amount or any
part thereof.

 

4.          Amendment;
Resignation or Removal of Escrow Agent. This Agreement may be altered or amended only with the written consent of the Company,
the Investor and the Escrow Agent. The Escrow Agent may resign and be discharged from its duties hereunder at any time by giving
written notice of such resignation to the Company and the Investor specifying a date when such resignation shall take effect and
upon delivery of the Shares to the successor escrow agent designated by the Company and Investor in writing. Such successor Escrow
Agent shall become the Escrow Agent hereunder upon the resignation date specified in such notice. If the Company and the Investor
fail to designate a successor Escrow Agent within thirty (30) days after such notice, then the resigning Escrow Agent shall promptly
refund the Shares to the Company. The Escrow Agent shall continue to serve until its successor accepts the escrow and receives
the Shares. Upon its resignation and delivery of the Shares as set forth in this Section 4, the Escrow Agent shall be discharged
of and from any and all further obligations arising in connection with the escrow contemplated by this Agreement. The resigning
Escrow Agent shall be entitled to be reimbursed by the Company and the Investor for any expenses incurred in connection with its
resignation, transfer of the Shares to a successor escrow agent or distribution of the Shares pursuant to this Section 4.

 

    	2

    	 

    

 

5.          Representations
and Warranties. The Company and the Investor hereby, severally represent and warrant to the Escrow Agent that:

 

5.1           No
party other than the parties hereto have, or shall have, any lien, claim or security interest in the Shares or any part thereof.

 

5.2           No
financing statement under the Uniform Commercial Code is on file in any jurisdiction claiming a security interest in or describing
(whether specifically or generally) the Shares or any part thereof.

 

5.3           All
of the information contained in this Agreement is, as of the date hereof, and will be, at the time of any disbursement of the Shares,
true and correct.

 

6.          Indemnification
and Contribution.

 

6.1           The
Company and the Investor (together, the “Indemnitors”) agree to indemnify the Escrow Agent and its officers,
directors, employees, agents and shareholders (collectively referred to as the “Indemnitees”) against, and hold
them harmless of and from, any and all loss, liability, cost, damage and expense, including without limitation, reasonable counsel
fees, which the Indemnitees may suffer or incur by reason of any action, claim or proceeding brought against the Indemnitees arising
out of or relating in any way to this Agreement or any transaction to which this Agreement relates, unless such action, claim or
proceeding is the result of the willful misconduct or gross negligence of any or all of the Indemnitees.

 

6.2           If
the indemnification provided for in Section 6.1 is applicable, but for any reason is held to be unavailable, the Indemnitors shall
contribute such amounts as are just and equitable to pay, or to reimburse the Indemnitees for, the aggregate of any and all losses,
liabilities, costs, damages and expenses, including counsel fees, actually incurred by the Indemnitees as a result of or in connection
with, and any amount paid in settlement of, any action, claim or proceeding arising out of or relating in any way to any actions
or omissions of the Indemnitors or any one of them.

 

6.3           The
provisions of this Article 6 shall survive any termination of this Agreement, whether by disbursement of the Escrow Amount, resignation
of the Escrow Agent or otherwise.

 

7.          Termination
of Agreement. This Agreement shall terminate on the final disposition of the Shares pursuant to Section 2, provided that the
rights of the Escrow Agent and the obligations of the other parties hereto shall survive the termination hereof and the resignation
or removal of the Escrow Agent.

 

    	3

    	 

    

 

8.          Governing
Law and Assignment. This Agreement shall be construed in accordance with and governed by the laws of the State of New York,
without regard to the conflicts of laws principles thereof, and shall be binding, upon the parties hereto and their respective
successors and assigns; provided, however, that any assignment or transfer by any party of its rights under this
Agreement or with respect to the Escrow Amounts shall be void as against the Escrow Agent unless (a) written notice thereof shall
be given to the Escrow Agent; and (b) the Escrow Agent shall have consented in writing to such assignment or transfer.

 

9.          Notices.
All notices required to be given in connection with this Agreement shall be sent by (i) facsimile transmission or email in portable
document format (.pdf), (ii) registered or certified mail, return receipt requested, (iii) hand delivery with receipt acknowledged,
or (iv) by the Express Mail service offered by the United States Postal Service, and addressed, if to the Buyer or Investor, at
their respective address set forth above, and if to the Escrow Agent, at its address set forth above.

 

10.         Severability.
If any provision of this Agreement or the application thereof to any person or circumstance shall be determined to be invalid or
unenforceable, the remaining provisions of this Agreement or the application of such provision to persons or circumstances other
than those to which it is held invalid or unenforceable shall not be affected thereby and shall be valid and enforceable to the
fullest extent permitted by law.

 

11.         Execution
in Several Counterparts. This Agreement may be executed in several counterparts or by separate instruments and by facsimile
transmission, and all of such counterparts and instruments shall constitute one agreement, binding on all of the parties hereto.

 

12.         Entire
Agreement. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof
and supersedes all prior agreements and understandings (written or oral) of the parties in connection therewith. If any conflict
arises between this Agreement and the Option Agreement, the Option Agreement shall control.

 

    	4

    	 

    

 

IN WITNESS WHEREOF, the undersigned have
executed this Agreement as of the day and year first above written.

 

	 	MATTHEW MCMURDO, ESQ.
	 	 
	 	/s/ Matthew McMurdo

	 	 
	 	COMPANY
	 	Axxess Pharama, Inc.

	 	 
	 	/s/ Peter Daniel Bagi

	 	Name: Peter Daniel Bagi
	 	Title Chief Executive Officer
	 	 
	 	INVESTOR
	 	Beaufort Capital Partners LLC

	 	 
	 	/s/ Leib Schaeffer

	 	Name: Leib Schaeffer
	 	Title: Managing Member

 

    	5Exhibit 10.19

 

Seaside 88, LP

750 Ocean Royale Way

Suite 1101

Juno Beach, FL 33408

 

January 8, 2015

 

Axxess Pharma, Inc.

2681 Eglinton Ave West

Toronto, Ontario M6M IT8

Canada

 

Gentlemen:

 

Reference is made to
that certain Securities Purchase Agreement (the “Agreement”), dated as of May 19, 2014, by and between Axxess Pharma,
Inc., a Nevada corporation (the “Company”), and Seaside 88, LP, a Florida limited partnership (such investor, including
its successors and assigns, “Seaside”), pursuant to which the Company agreed to issue and sell, and Seaside agreed
to purchase, up to 5,000,000 shares of the common stock, par value $0.0001 per share, of the Company upon the terms and subject
to the conditions set forth therein. Capitalized terms used herein without definition shall have the meanings assigned to such
terms in the Agreement.

 

At the Initial Closing
under the Agreement on May 20, 2014, Seaside purchased 584,350 shares of Common Stock; at two Subsequent Closings under the Agreement,
on June 20, 2014 and July 20, 2014, Seaside purchased an additional 917,300 shares and 840,520 shares, respectively, of Common
Stock. As of the date of this letter agreement, Seaside owns an aggregate 2,342,170 shares of the Common Stock of the Company,
all of which shares are restricted and cannot be sold unless registered under the Securities Act or an exemption therefrom is available.
No further Subsequent Closings have occurred under the Agreement as of the date of this letter agreement, the shares have not been
registered under an effective registration statement filed pursuant to the Securities Act, and no exemption is currently available
to Seaside to sell its shares.

 

    	 

    	 

    

 

In Section 4.2 of the
Agreement, the Company covenanted and agreed to become a reporting company under the Exchange Act, subject to the reporting requirements
of Section 13 or 15(d) thereof, no later than three months following the date of the Agreement, and thereafter to file all reports
required to be filed by a reporting company pursuant to Section 13 or Section 15(d) of the Exchange Act. Section 4.2 also provides
that in the event there is a delay for any reason in the Company becoming a reporting company such that at the six month anniversary
of the Initial Closing Date (the “Trigger Date”), the Company would not have been subject to the reporting requirements
of the Exchange Act for a period of at least 90 days prior to the Trigger Date as required by Rule 144, then the Company would
have an additional 30 day period following the Trigger Date to gain compliance with the requirements of such Rule and the penalties
set forth in Section 4.1(d) and Section 4.2(c) of the Agreement would not be available or payable to Seaside during such 30 day
period. The penalties set forth in Section 4.1(d) and Section 4.2(c) would thereafter be available and payable to Seaside following
the expiration of such 30 day period following the Trigger Date. Section 4.2(c) entitles Seaside to be paid by the Company, in
cash, as liquidated damages and not as a penalty, for each $1,000 of Shares (valued based on the VWAP of the Common Stock on the
date on which Seaside first attempts a sale) sought to be sold by Seaside, $10 per Trading Day (increasing to $20 per Trading Day
ten (10) Trading Days after such damages have begun to accrue) for each Trading Day that a Public Information Failure remains uncured
by the Company. Such Public Information Failure Payments are to be paid by the Company to Seaside within five Business Days
of the first occurrence of the Public Information Failure and on or before the last day of each calendar month thereafter if the
Public Information Failure continues beyond the first month.  In the event the Company fails to make Public Information Failure
Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month
(prorated for partial months) until paid in full.

 

The Company agrees
and acknowledges that a Public Information Failure under the Agreement has occurred and is continuing and that Public Information
Failure Payments are due and owing to Seaside under Section 4.2(c) of the Agreement. Seaside agrees to waive such Public Information
Failure and agrees to waive any Public Information Failure Payments (including any interest accrued thereon) due and owing to Seaside
through March 30, 2015 (the “Deadline”) in exchange for the issuance on the date hereof to Seaside of One Hundred Thousand
(100,000) shares of Common Stock of the Company, which shares shall be included in and registered for resale pursuant to the Company’s
Registration Statement on Form S-1, Reg. Stmt. No. 333-197647. The parties further agree and acknowledge that commencing the day
immediately following the Deadline, any Public Information Failure of the Company under the Agreement that remains uncured as of
such day shall entitle Seaside to Public Information Failure Payments under Section 4.2(c) of the Agreement, calculated commencing
on such day. Any other damages that may be due and owing to Seaside following the Deadline, including under Section 4.1(d) of the
Agreement, shall also commence and be payable starting on such day until the breach giving rise to such damage has been cured by
the Company.

 

Except as otherwise
expressly provided in this letter agreement, all provisions of the Agreement are hereby ratified and agreed to be in full force
and effect, and are incorporated herein by reference. This letter agreement and the Agreement constitute the entire agreement between
the parties with respect to the subject matter hereof, and supersede all prior written agreements and negotiations and oral understandings,
if any, with respect to such subject matter. This letter agreement may be executed in separate counterparts, each of which shall
be deemed an original, and all of which taken together shall constitute one and the same instrument.

 

    	 

    	 

    

 

If you are in agreement
with the foregoing, please signify your acceptance below. This letter agreement shall expire at 5:00 PM EST on Friday,
January 9, 2015 unless accepted in writing below, and will terminate if not accepted, by such time and date.

 

	 	Seaside 88, LP
	 	 
	 	By:	Seaside 88 Advisors, LLC
	 	 	 
	 	By:	/s/ William J. Ritger
	 	 	William J. Ritger
	 	 	Manager

 

Accepted and agreed this 9th day of
January, 2015:

 

Axxess Pharma, Inc.

 

	By:	Peter Daniel Bagi	 
	 	Daniel Bagi, MD	 
	 	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]